Biogen Reports Finding New Approach to MS Treatments

Biogen Idec reports that inhibiting death receptor-6 (DR6) function may represent a novel target for treating multiple sclerosis (MS). The study, published in Nature Medicine, showed that blocking DR6 function promoted axonal remyelination. Although the present study focused on MS, promoting axonal remyelination could potentially benefit ALS.

Click here to read more.

Share this: